EMA
research
· 2017-09-15
Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes
Summary
A European Medicines Agency assessment concludes there is no clear or consistent evidence that different classes of Factor VIII medicines differ in the risk of …
Upgrade for the full analysis, importance score, and drug timeline.